|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NAT1 |
Gene summary for NAT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NAT1 | Gene ID | 9 |
| Gene name | N-acetyltransferase 1 | |
| Gene Alias | AAC1 | |
| Cytomap | 8p22 | |
| Gene Type | protein-coding | GO ID | GO:0006805 | UniProtAcc | P18440 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9 | NAT1 | GSM4909293 | Human | Breast | IDC | 2.14e-20 | 2.94e-01 | 0.1581 |
| 9 | NAT1 | GSM4909301 | Human | Breast | IDC | 1.08e-04 | 1.77e-01 | 0.1577 |
| 9 | NAT1 | GSM4909302 | Human | Breast | IDC | 2.03e-04 | 2.38e-01 | 0.1545 |
| 9 | NAT1 | GSM4909307 | Human | Breast | IDC | 6.51e-27 | 5.45e-01 | 0.1569 |
| 9 | NAT1 | GSM4909308 | Human | Breast | IDC | 5.04e-70 | 9.70e-01 | 0.158 |
| 9 | NAT1 | GSM4909317 | Human | Breast | IDC | 7.99e-15 | 3.46e-01 | 0.1355 |
| 9 | NAT1 | GSM4909318 | Human | Breast | IDC | 3.03e-07 | 6.66e-01 | 0.2031 |
| 9 | NAT1 | GSM4909321 | Human | Breast | IDC | 5.62e-10 | 4.10e-01 | 0.1559 |
| 9 | NAT1 | NCCBC11 | Human | Breast | DCIS | 1.04e-06 | 6.00e-01 | 0.1232 |
| 9 | NAT1 | NCCBC3 | Human | Breast | DCIS | 2.50e-23 | 5.17e-01 | 0.1198 |
| 9 | NAT1 | P3 | Human | Breast | IDC | 6.97e-04 | 3.71e-01 | 0.1542 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| GO:000636410 | Oral cavity | OSCC | rRNA processing | 172/7305 | 225/18723 | 1.57e-30 | 1.24e-27 | 172 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:001607210 | Oral cavity | OSCC | rRNA metabolic process | 176/7305 | 236/18723 | 6.51e-29 | 3.24e-26 | 176 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:00447728 | Oral cavity | OSCC | mitotic cell cycle phase transition | 255/7305 | 424/18723 | 5.29e-19 | 6.98e-17 | 255 |
| GO:000641720 | Oral cavity | OSCC | regulation of translation | 274/7305 | 468/18723 | 4.39e-18 | 4.63e-16 | 274 |
| GO:004572719 | Oral cavity | OSCC | positive regulation of translation | 101/7305 | 136/18723 | 5.85e-17 | 4.94e-15 | 101 |
| GO:004227420 | Oral cavity | OSCC | ribosomal small subunit biogenesis | 63/7305 | 73/18723 | 7.61e-17 | 6.34e-15 | 63 |
| GO:003425019 | Oral cavity | OSCC | positive regulation of cellular amide metabolic process | 115/7305 | 162/18723 | 1.28e-16 | 1.05e-14 | 115 |
| GO:00330448 | Oral cavity | OSCC | regulation of chromosome organization | 123/7305 | 187/18723 | 9.87e-14 | 5.17e-12 | 123 |
| GO:005105210 | Oral cavity | OSCC | regulation of DNA metabolic process | 207/7305 | 359/18723 | 4.45e-13 | 2.17e-11 | 207 |
| GO:00435434 | Oral cavity | OSCC | protein acylation | 149/7305 | 243/18723 | 1.33e-12 | 5.80e-11 | 149 |
| GO:007190010 | Oral cavity | OSCC | regulation of protein serine/threonine kinase activity | 201/7305 | 359/18723 | 3.90e-11 | 1.27e-09 | 201 |
| GO:00064734 | Oral cavity | OSCC | protein acetylation | 124/7305 | 201/18723 | 5.59e-11 | 1.74e-09 | 124 |
| GO:00304903 | Oral cavity | OSCC | maturation of SSU-rRNA | 41/7305 | 50/18723 | 5.59e-10 | 1.46e-08 | 41 |
| GO:000072316 | Oral cavity | OSCC | telomere maintenance | 85/7305 | 131/18723 | 1.72e-09 | 4.09e-08 | 85 |
| GO:001063918 | Oral cavity | OSCC | negative regulation of organelle organization | 190/7305 | 348/18723 | 2.12e-09 | 4.97e-08 | 190 |
| GO:00457879 | Oral cavity | OSCC | positive regulation of cell cycle | 173/7305 | 313/18723 | 3.28e-09 | 7.44e-08 | 173 |
| GO:004873220 | Oral cavity | OSCC | gland development | 226/7305 | 436/18723 | 2.78e-08 | 5.39e-07 | 226 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NAT1 | SNV | Missense_Mutation | c.655N>A | p.Gly219Arg | p.G219R | protein_coding | deleterious(0.02) | possibly_damaging(0.887) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| NAT1 | insertion | Frame_Shift_Ins | rs746311173 | c.486dupA | p.Tyr163IlefsTer15 | p.Y163Ifs*15 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| NAT1 | insertion | In_Frame_Ins | novel | c.1043_1044insGCCTCTCTC | p.Arg348_Phe349insProLeuSer | p.R348_F349insPLS | protein_coding | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |||
| NAT1 | SNV | Missense_Mutation | novel | c.37N>A | p.Glu13Lys | p.E13K | protein_coding | possibly_damaging(0.502) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
| NAT1 | SNV | Missense_Mutation | c.1014G>C | p.Gln338His | p.Q338H | protein_coding | tolerated(0.07) | possibly_damaging(0.477) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NAT1 | SNV | Missense_Mutation | novel | c.689N>C | p.Gln230Pro | p.Q230P | protein_coding | tolerated(0.18) | benign(0.057) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| NAT1 | SNV | Missense_Mutation | rs138061602 | c.377G>A | p.Arg126Gln | p.R126Q | protein_coding | deleterious(0.02) | possibly_damaging(0.903) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NAT1 | SNV | Missense_Mutation | novel | c.689A>G | p.Gln230Arg | p.Q230R | protein_coding | tolerated(0.08) | benign(0.057) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NAT1 | SNV | Missense_Mutation | c.974N>G | p.Ile325Arg | p.I325R | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | ||
| NAT1 | SNV | Missense_Mutation | novel | c.473N>A | p.Thr158Asn | p.T158N | protein_coding | tolerated(0.2) | benign(0.005) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9 | NAT1 | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1201023 | ORPHENADRINE HYDROCHLORIDE | |
| 9 | NAT1 | ENZYME, DRUGGABLE GENOME | CHEMBL1201483 | PSEUDOEPHEDRINE POLISTIREX | ||
| 9 | NAT1 | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1898523 | PHENDIMETRAZINE TARTRATE | |
| 9 | NAT1 | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL3301595 | DASOTRALINE | |
| 9 | NAT1 | ENZYME, DRUGGABLE GENOME | CHEMBL1200992 | |||
| 9 | NAT1 | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1237135 | MAPROTILINE HYDROCHLORIDE | |
| 9 | NAT1 | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1722 | METHYLPHENIDATE HYDROCHLORIDE | |
| 9 | NAT1 | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1200492 | NEFAZODONE HYDROCHLORIDE | |
| 9 | NAT1 | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL2105732 | LEVOMILNACIPRAN HYDROCHLORIDE | |
| 9 | NAT1 | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL2103857 | EDIVOXETINE |
| Page: 1 2 3 4 5 6 7 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |